Literature DB >> 1721823

Cytokines in clinical cancer therapy.

H F Oettgen1.   

Abstract

Cytokines have been of much interest in clinical cancer therapy research over the past decade. One important advance during the past year has been the clear demonstration, in large prospective randomized studies, that granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor reduce the neutropenia-related morbidity of cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721823     DOI: 10.1016/0952-7915(91)90099-m

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  3 in total

1.  Activity of a short course of interferon alpha for metastatic renal cell carcinoma--a phase-2 study.

Authors:  R P Abratt; A R Pontin; H S Ball
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 2.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

3.  Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies.

Authors:  P Pisa; E Halapi; E K Pisa; E Gerdin; C Hising; A Bucht; B Gerdin; R Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.